GRAIL, Inc. (GRAL) vs NeoGenomics, Inc. (NEO)
GRAIL, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $5.5B against $2.5B — 2.2× the size. GRAIL, Inc. grew revenue faster over the last twelve months: 23.1% against 11.2%. NeoGenomics, Inc. has the higher net margin (−6.77% vs −237.0%) and the higher return on invested capital (−4.20% vs −20.8%). Across the 17 metrics below, NeoGenomics, Inc. leads on 12 and GRAIL, Inc. on 5.
Valuation
Profitability
| Metric | GRAL | NEO | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | (31.31%) | 43.92% | 50.89% |
| Operating margin | (338.40%) | (8.93%) | (8.57%) |
| Net margin | (236.95%) | (6.77%) | (6.37%) |
| Free cash flow margin | (179.21%) | (0.69%) | 0.00% |
| Return on equity | (16.12%) | (6.33%) | (2.92%) |
| Return on assets | (14.12%) | (3.78%) | (6.71%) |
| Return on invested capital | (20.79%) | (4.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack